Literature DB >> 16815654

Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers.

Deirdre O Corrigan1, Owen I Corrigan, Anne Marie Healy.   

Abstract

The physicochemical and aerodynamic properties of spray dried powders of the drug/drug mixture salbutamol sulphate/ipratropium bromide were investigated. The in vitro deposition properties of spray dried salbutamol sulphate and the spray dried drug/excipient mixtures salbutamol sulphate/lactose and salbutamol sulphate/PEG were also determined. Spray drying ipratropium bromide monohydrate resulted in a crystalline material from both aqueous and ethanolic solution. The product spray dried from aqueous solution consisted mainly of ipratropium bromide anhydrous. There was evidence of the presence of another polymorphic form of ipratropium bromide. When spray dried from ethanolic solution the physicochemical characterisation suggested the presence of an ipratropium bromide solvate with some anhydrous ipratropium bromide. Co-spray drying salbutamol sulphate with ipratropium bromide resulted in amorphous composites, regardless of solvent used. Particles were spherical and of a size suitable for inhalation. Twin impinger studies showed an increase in the fine particle fraction (FPF) of spray dried salbutamol sulphate compared to micronised salbutamol sulphate. Co-spray dried salbutamol sulphate:ipratropium bromide 10:1 and 5:1 systems also showed an increase in FPF compared to micronised salbutamol sulphate. Most co-spray dried salbutamol sulphate/excipient systems investigated demonstrated FPFs greater than that of micronised drug alone. The exceptions to this were systems containing PEG 4000 20% or PEG 20,000 40% both of which had FPFs not significantly different from micronised salbutamol sulphate. These two systems were crystalline unlike most of the other spray dried composites examined which were amorphous in nature.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16815654     DOI: 10.1016/j.ijpharm.2006.05.022

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  6 in total

1.  Pulmonary spray dried powders of tobramycin containing sodium stearate to improve aerosolization efficiency.

Authors:  Chiara Parlati; Paolo Colombo; Francesca Buttini; Paul M Young; Handoko Adi; Alaina J Ammit; Daniela Traini
Journal:  Pharm Res       Date:  2009-01-31       Impact factor: 4.200

2.  Preparation of 5-fluorouracil nanoparticles by supercritical antisolvents for pulmonary delivery.

Authors:  Pardis Kalantarian; Abdolhosein Rouholamini Najafabadi; Ismaeil Haririan; Alireza Vatanara; Yadollah Yamini; Majid Darabi; Kambiz Gilani
Journal:  Int J Nanomedicine       Date:  2010-10-05

3.  Puerarin dry powder inhaler formulations for pulmonary delivery: Development and characterization.

Authors:  Md Abdur Rashid; Saiqa Muneer; Tony Wang; Yahya Alhamhoom; Llew Rintoul; Emad L Izake; Nazrul Islam
Journal:  PLoS One       Date:  2021-04-13       Impact factor: 3.240

4.  Formulation and evalution of montelukast sodium - chitosan based spray dried microspheres for pulmonary drug delivery.

Authors:  Rushi Panchal; Harsha Patel; Vishnu Patel; Pratik Joshi; Ankit Parikh
Journal:  J Pharm Bioallied Sci       Date:  2012-03

5.  Excipient Interactions in Glucagon Dry Powder Inhaler Formulation for Pulmonary Delivery.

Authors:  Md Abdur Rashid; Amged Awad Elgied; Yahya Alhamhoom; Enoch Chan; Llew Rintoul; Ayman Allahham; Nazrul Islam
Journal:  Pharmaceutics       Date:  2019-05-01       Impact factor: 6.321

6.  Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation.

Authors:  Ditte Marie Krohn Jensen; Dongmei Cun; Morten Jonas Maltesen; Sven Frokjaer; Hanne Mørck Nielsen; Camilla Foged
Journal:  J Control Release       Date:  2009-10-22       Impact factor: 9.776

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.